Press release from PR Newswire
Hologic to Release First Quarter Fiscal 2012 Operating Results on Monday, January 30, 2012
Monday, December 19, 2011
Hologic to Release First Quarter Fiscal 2012 Operating Results on Monday, January 30, 201216:01 EST Monday, December 19, 2011BEDFORD, Mass., Dec. 19, 2011 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced plans to release its first quarter fiscal 2012 operating results on Monday, January 30, 2012 after market close. In conjunction with the release, management will host a conference call on Monday, January 30, 2012, at 5:00 p.m. (eastern).Interested participants may listen to the call by dialing 877-857-6163 or 719-325-4794 for international callers and referencing code 5969459 approximately 15 minutes prior to the call on January 30th. For those unable to participate in the live broadcast, a replay will be available one hour after the call ends through Friday, February 17, 2012, at 888-203-1112 or 719-457-0820 for international callers, access code 5969459.The Company will also provide a live webcast of the call. Interested participants may access the webcast on the Company's website at www.hologic.com/investors-overview. A replay of the call will be archived on the Company's website.About Hologic, Inc. Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, breast magnetic resonance imaging, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia and uterine fibroids, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including reagents for a variety of DNA and RNA analysis applications. For more information, visit www.hologic.com.Contact: Deborah R. Gordon Vice President, Investor Relations Hologic, Inc. (781) 999-7716SOURCE Hologic, Inc.